01—Abstract
Summary
Summary of the 10-K filed March 31, 2005. Cited figures are marked; the original filing is the authoritative source.
Biogen Idec's 2004 10-K (filed March 31, 2005) reports total revenues of $2.21 billiona, up from $679 million in 2003, but the year was defined by a sharp reversal in February 2005.
Net income was only $25.1 millionb ($0.07 diluted EPS) and was dragged down by $289.5 million of purchase-accounting inventory step-up, $347.7 million of acquired-intangible amortization, and $686.7 million of R&D. Growth was driven by the November 2003 Merger with Biogen, Inc., which brought in AVONEX ($1.42 billion in 2004 sales) and a full year of the RITUXAN copromotion. AVONEX and RITUXAN together made up about 92% of revenue, so concentration risk is high.
The central investor issue is TYSABRI. After its November 2004 FDA approval, the company and Elan voluntarily suspended marketing and dosing in February 2005 following two cases of progressive multifocal leukoencephalopathy (PML), and a March 30, 2005 review reassessed a Crohn's trial death as PML. Management cannot predict whether TYSABRI can be reintroduced.
The filing discloses possible inventory and intangible write-offs, goodwill impairment risk, and facility impairments tied to the product. It also discloses multiple securities class actions, derivative suits, a demand letter, and an SEC informal inquiry related to insider stock sales. Balance-sheet and liquidity pressure is also significant.
Senior convertible notes of about $753 millionc become puttable on April 29, 2005, and the company expects that a cash outflow of up to about $809 million will likely occur, which it plans to fund by liquidating marketable securities. Cash, equivalents and marketable securities fell to $2.2 billion. The company also repurchased about $734 million of stock in 2004, and its 2005 SG&A and R&D are expected to rise.
02—Key points
Key Highlights
- Total 2004 revenue of $2,211.6M, up from $679.2M in 2003, largely reflecting the full-year inclusion of the Biogen, Inc. Merger (November 2003).
- Net income fell to $25.1M ($0.07 diluted EPS) versus a $875.1M net loss in 2003, which included an $823M IPR&D write-off. 2004 earnings were held down by $289.5M of inventory step-up and $347.7M of intangible amortization.
- AVONEX generated $1.42B in 2004 sales and RITUXAN U.S. copromotion profits plus royalties were $457M and $121M respectively; AVONEX and RITUXAN together were ~92% of revenue.
- TYSABRI was approved by the FDA in November 2004 but suspended in February 2005 after two PML cases; a March 2005 review reclassified a Crohn's trial death as PML. Re-launch timing and outcome are uncertain, and TYSABRI inventory was fully written down ($19.1M) with an additional $22–25M expected in Q1 2005.
- Senior convertible notes (~$753M principal, ~$809M total cash outflow) are puttable on April 29, 2005, and the company expects a substantial portion to be repurchased, requiring liquidation of marketable securities.
- Significant litigation: securities class actions (Brown, Grill), multiple shareholder derivative suits in Delaware and California, shareholder demand letters, an SEC informal inquiry, Columbia University royalty dispute, Classen patent suit, and multistate Average Wholesale Price/Medicaid suits.
- The company repurchased about $734M of stock in 2004 and has ~19.4M shares remaining under the October 2004 program; cash and marketable securities declined to $2.17B at year end.
03—Questions
Frequently Asked Questions
Why did the TYSABRI suspension matter so much for investors?
TYSABRI was positioned as a major growth driver and was approved only months before the suspension. Two PML cases in patients on TYSABRI plus AVONEX led to a voluntary suspension of marketing and dosing in February 2005. The company says it cannot predict whether TYSABRI will return to market, and an unfavorable outcome could mean permanent withdrawal, label restrictions, or EU approval problems. The filing also flags possible write-offs of inventory, intangibles, goodwill, and facilities, plus a potential workforce impact.
How much cash does the company need to repurchase its senior notes in April 2005?
Holders of the 1.75% senior convertible notes due 2032 can require repurchase on April 29, 2005. The aggregate purchase price is about $753 million, and the total potential cash outflow including tax is up to about $809 million. Management said it is highly probable that all or a substantial portion will be repurchased and that it would liquidate part of its marketable securities to fund this.
Is the 2004 profit reliable as a guide to earnings power?
Not fully. Reported 2004 net income of $25.1M was held down by about $289.5M of purchase-accounting inventory step-up from the Merger and $347.7M of acquired-intangible amortization, and it benefited from a roughly 61% effective tax rate. Management expects gross margins to improve in 2005 because the acquired inventory has been sold, but it also expects higher SG&A and R&D and notes that TYSABRI-related charges could follow.
How concentrated is the revenue base?
Highly concentrated. AVONEX and RITUXAN represented about 92% of 2004 total revenue. AVONEX faces competition from REBIF, BETASERON, and COPAXONE, and RITUXAN's U.S. economics flow through a profit-sharing arrangement with Genentech that resets annually. Much of the RITUXAN value reaches the company as copromotion profit and royalties rather than direct product sales.
What legal exposure does the company face beyond TYSABRI?
The filing describes Medicaid and Average Wholesale Price suits in New York (including RICO claims, some partly dismissed), a Columbia University patent royalty dispute, the Classen immunization patent suit, and an SEC informal inquiry into insider trading around the TYSABRI suspension. Management said it cannot estimate potential losses for most matters and believes most are without merit, but it cautions that adverse outcomes could be material.
04—Continue